Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
8/8 18:00
For weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares. Industry pioneer Novo Nordisk A/S (NYSE: NVO) saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly (NYSE: LLY) shares fell ap...